

REMARKS

Claims 1-86 and 88 were previously cancelled. Accordingly, Claims 87 and 89-100 are currently pending.

Claim Objections

The Examiner suggests that the term “polypeptide” in all the claims be replaced with “antibody.” (See Office Action, page 2, paragraph 4.) Accordingly, all the claims have been amended to replace “polypeptide” with “antibody or fragment thereof.”

Rejections under 35 U.S.C. §112, first paragraph

Claims 87, 89 and 91-100 are rejected under 35 U.S.C. §112, first paragraph, as allegedly not being fully enabled.


In particular, the Examiner alleges that the specification is not enabling for antibodies wherein the heavy chain variable region comprises SEQ. ID. NO: 27 or SEQ. ID. NO: 28. (See Office Action page 2, paragraph 6.) Accordingly, the recitation of SEQ. ID. NO: 27 and SEQ. ID. NO: 28 has been deleted from Claims 87, 89 and 91-97. Thus, the rejection is obviated.

Additionally, the Examiner rejects Claims 98-100 as reciting “*in vivo* intended use.” (See Office Action, page 3, 2nd full paragraph.) Accordingly, the phrase “for the treatment of factor VIII inhibition in a human individual” has been deleted from the claims. Thus, the rejection is obviated.

Application Serial No. 09/674,752
Filing Date: December 29, 2000.
Docket: 294-86 PCT/US/RCE II
Page 6 of 6

For the above reasons, allowance of the pending claims is earnestly requested. If the Examiner has any questions regarding this amendment, he is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Susan A. Sipos', written over a horizontal line.

Susan A. Sipos
Registration No. 43,128
Attorney for Applicants

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
Tel. 516-822-3550
Fax. 516-822-3582
SAS
282929